BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer, and Eric
d'Esparbes, the Company's Senior Vice President and Chief Financial
Officer, will participate in a fireside chat at the Bank of America
Merrill Lynch 2017 Healthcare Conference in Las Vegas on Wednesday, May
17 from 4:20 p.m. to 4:50 p.m. PT.
The presentation will be webcast live and a replay will be available one
hour after the conclusion of the live event through August 15, 2017 by
following this link: Innoviva
at BofAML or via the investor relations section of the Innoviva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO®
ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest
in future payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc., including the closed triple combination
therapy for Chronic Obstructive Pulmonary Disease (COPD). For more
information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170510005351/en/
Eric d'Esparbes, 650-238-9640
President and Chief Financial Officer
Source: Innoviva, Inc.
News Provided by Acquire Media